Fecal Calprotectin, Human, Rapid ELISA kit
Calprotectin, also known as S100A8/A9 heterocomplex, is formed out of the calcium-binding, migrating proteins S100A8 and S100A9. Calprotectin is a calcium- and zinc-binding protein complex composed of 8 and 14 kD subunits and complex formation is calcium dependent. Neutrophils are the main producers of calprotectin, but expression has also been found in monocytes, macrophages and ileal tissue eosinophils. Altogether, S100A8 and S100A9 proteins contribute to approximately 40–60% of the soluble, cytosolic content of granulocytes. Calprotectin has antibacterial, antifungal, immunomodulating and antiproliferative effects. Elevated concentrations of calprotectin can be measured among others in plasma, synovial fluid, urine and feces. The presence of calprotectin in feces quantitatively relates to neutrophil migration towards the gastrointestinal tract.
Calprotectin is therefore considered a reliable biomarker for intestinal inflammation throughout the gastrointestinal tract. Calprotectin in feces is stable for several days and even longer at 4 °C. Consistently higher fecal calprotectin levels have been reported in both adult and pediatric patients with IBD compared to IBS or healthy controls. Raised levels of the protein indicate presence of luminal white cells. Such finding indicates that the intestine is inflamed, although the type of inflammation is not defined.
The ELISA is a single incubation step reaction. After this incubation the wells are filled with substrate. The obtained color intensity is proportional to the amount of calprotectin in your sample. The amount of calprotectin can be calculated based on the standard curve of calibrated native calprotectin. The test performance is assured by the addition of a high control and a low control.
You may also like…
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA